Press Releases

Second quarter 2026 reported and adjusted* operating income decreased 31% and 5% compared to the second quarter 2025Second quarter 2026 reported and adjusted EPS were $1.78 and $2.82, compared with $2.99 and $2.87 in the second quarter 2025Reaffirming amended full-year guidance, which now reflects the sale of a majority stake in the Pakistan business, for reported EPS to be in the range of $9.15 to $9.75 and adjusted EPS to be in the range of $10.30 to $10.90Ingredion’s 595 pence all-cash offer to acquire Tate & Lyle accepted by their shareholders WESTCHESTER, Ill., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Ingredion Incorporated (NYSE:INGR), a leading global provider of ingredient solutions to t

UBRELVY® (ubrogepant) positive recommendation by Canada's Drug Agency (CDA-AMC) is supported by evidence from the pivotal Phase 3 ACHIEVE I and ACHIEVE II studies.CDA-AMC recommendation recognizes the need for additional migraine-specific acute treatment options for adults.Migraine affects an estimated 5 million Canadians with the highest prevalence in women1 and individuals in their 30s and 40s.2MONTREAL, Aug. 4, 2026 /CNW/ -- AbbVie (NYSE:ABBV) announced today that Canada's Drug Agency (CDA-AMC) has recommended UBRELVY® (ubrogepant) be reimbursed with conditions by public drug plans for the acute treatment of migraine, with or without aura, in adults with a history of migraine attacks with

Paris, France--(Newsfile Corp. - August 4, 2026) - Sequans Communications S.A. (NYSE:SQNS) ("Sequans" or the "Company"), a leading provider of 5G/4G cellular IoT semiconductor solutions, today announced preliminary unaudited financial results for the second quarter ended June 30, 2026.Second Quarter 2026 Summary Preliminary Unaudited Results Table:(in US$ millions, except share and per share data)Q2 2026Q1 2026 (1)Q2 2025 (2)Revenue $7.5 $6.1 $8.1 Gross profit $2.5 $2.3 $5.2 Gross margin (%) 32.9 % 37.7 % 64.4 %Operating income (loss) ($7.2) ($50.5) ($8.5) Net profit (loss) ($9.8) ($76.2) ($9.0) Diluted income (loss) per ADS ($0.65) ($5.23) ($3.53) Non-IFRS diluted income (loss) p

Exceeds Second Quarter 2026 GuidanceRaises Full Year 2026 GuidanceSecond Quarter 2026 HighlightsNet Sales of $1.8 billion increased 4%; organic sales increased 4% versus year-ago periodGAAP Income from continuing operations of $191 million; operating EBITDA of $448 millionGAAP EPS from continuing operations of $1.37; adjusted EPS of $1.88Cash provided by operating activities from continuing operations of $400 million; transaction-adjusted free cash flow of $326 million representing 127% conversionAnnounces intent to repurchase $250 million of shares in the third quarterAnnounces the Company's Global Industry Classification Standard (GICS) code has changed to Industrials effective July 31, 20

Revenues of $4.6 billion, up 7% year-over-yearNet income of $356 million or $2.81 per diluted shareAdjusted EBITDA (non-GAAP) of $631 million and Adjusted EBITDA margin (non-GAAP) of 13.8%Non-GAAP Diluted Earnings per Share of $3.26, up 2% year-over-yearCash Flows from Operations of $793 million; Non-GAAP Free Cash Flow of $761 millionRESTON, Va., Aug. 4, 2026 /PRNewswire/ -- Leidos Holdings, Inc. (NYSE:LDOS) today reported financial results for the second quarter of fiscal year 2026, highlighted by robust revenue growth and free cash flow generation. "I'm pleased to report another strong quarter for Leidos," said Chief Executive Officer Tom Bell. "In addition to achieving milestones for rev

Second Quarter 2026 HighlightsTotal reported revenue of $1.645 billion surpassed the high end of the guidance range, driven by broad-based outperformance across both organic revenue and the acquired businesses.Organic revenue of $828 million grew 7% as reported and 9% in constant currency; the Analytical Sciences Division (ASD) delivered 8% instrument growth and double-digit chemistry consumables growth, led by low-double-digit growth in both Pharma and A&G end markets, in constant currency, as the market recovery has entered a broader phase, expanding across additional customer segments.Biosciences and Diagnostic Solutions revenue of $817 million exceeded guidance by $15 million and grew 4%

Registrational OptimUM-02 trial of the darovasertib combination in metastatic uveal melanoma (mUM) met its primary endpoint; new drug application (NDA) filing is underway under the real-time oncology review program (RTOR) with completion expected in H2 2026Updated data from Phase 2 OptimUM-01 trial (HLA*A2-positive mUM patient subset) and Phase 2 OptimUM-09 trial (neoadjuvant primary UM) to be presented at ESMOUpdated data from Hengrui-sponsored Phase 1 trial of IDE849 (DLL3 TOP1 ADC) in small-cell lung cancer (SCLC) and neuroendocrine carcinomas (NEC) patients to be presented at ESMO Announced clinical collaboration with Roche to evaluate IDE892 (PRMT5) in combination with RG6505 (pan-RAS)

Completed transaction reflects continued execution toward a simplified and more efficient operating footprint.FORT LAUDERDALE, Fla. and BOISBRIAND, QC, Aug. 4, 2026 /PRNewswire/ -- Vision Marine Technologies Inc. (NASDAQ:VMAR, TSXV:VMAR) ("Vision Marine" or the "Company"), a marine technology and recreational boating company combining proprietary propulsion technology with direct consumer access through its Nautical Ventures retail, service and marina platform, today announced the completion of a property disposition under its previously announced Florida real estate and operational optimization plan through the closing of the sale of 1440 S. Federal Highway in Fort Lauderdale, Florida.

HighlightsSecond quarter U.S. GAAP total diluted earnings per share of 83 cents vs. 76 cents in 2025Second quarter comparable diluted earnings per share of $1.03 vs. 90 cents in 2025, an increase of 14.4%Second quarter comparable operating earnings of $433 million vs. $402 million in 2025, an increase of 7.7%Global aluminum packaging shipments increased 4.3% in the second quarterReturned $222 million to shareholders via share repurchases and dividends in the first six months of 2026; on track to return at least $800 million through share buybacks and dividends to shareholders by year-endIn 2026, expect comparable diluted earnings per share growth of 10-plus percent and free cash flow greater

Second quarter GAAP net income of $4.4 million or $0.08 per diluted common share and Distributable Earnings1 of $6.9 million or $0.12 per diluted common share- Subsequent to the three months ended June 30, 2026 -Declared third quarter 2026 dividend of $0.15 per common shareNEW YORK, Aug. 4, 2026 /PRNewswire/ -- Ares Commercial Real Estate Corporation (the "Company") (NYSE:ACRE), a specialty finance company primarily engaged in directly originating and investing in commercial real estate loans and related investments, reported generally accepted accounting principles ("GAAP") net income of $4.4 million or $0.08 per diluted common share and Distributable Earnings1 of $6.9 million or $0.12 per

Positioned To Accelerate Profitable Growth and Innovation as a Pure-Play Building Technologies Company Repaid $900 Million of Indebtedness and Preferred Stock Reduced to 350,000 Shares OutstandingADI Begins Trading Today on the New York Stock Exchange Under Ticker "ADIG"SCOTTSDALE, Ariz., Aug. 4, 2026 /PRNewswire/ -- Resideo Technologies, Inc. (NYSE:REZI) ("Resideo"), a leading global developer and manufacturer of critical control and sensing solutions for residential end markets, today announced the completion of its spin-off of ADI Global Distribution Inc. ("ADI"), establishing Resideo as a pure-play building technologies company. Resideo will continue to trade on the New York Stock Exchan

MELBOURNE, Fla., Aug. 4, 2026 /PRNewswire/ -- Eve Holding, Inc. ("Eve") (NYSE:EVEX) reports its second quarter 2026 earnings results. Financial HighlightsEve Air Mobility is an aerospace company dedicated to developing an eVTOL (electric Vertical Takeoff and Landing) aircraft and the Urban Air Mobility (UAM) ecosystem. This includes aircraft development, Services & Support solutions like Eve TechCare® and Eve Vector®, an Urban Air Traffic Management system. Eve is pre-operational.  We do not expect meaningful revenue, if any, during the aircraft development phase. Financial results during this period are expected to be driven mostly by program development costs.Eve reported a net loss of $34

AI-enabled customer operations achieve a 98.7% answer rate, nearly 80% autonomous problem resolution and approximately 1,500 hours of daily speech-to-text processingBEIJING, Aug. 4, 2026 /PRNewswire/ -- Yiren Digital Ltd. (NYSE:YRD) ("Yiren Digital" or the "Company"), a leading company specializing in financial technology and artificial intelligence innovation across multiple industries in China and global markets, today announced the continued expansion of AI deployment across customer operations, including intelligent customer service, outbound communications, quality controls and workflow automation. Customer operations encompass some of the Company's highest-volume workflows, spanning se

The Company Expects Record Revenue, Gross Profit and Adjusted EBITDA Ahead of Analyst ForecastsThe Company Also Announces Record Quarterly Distribution of Over 10 Tonnes of Medical Cannabis Flower Through Remexian Pharma GmbH, Further Accelerating its German Market PositionCALGARY, AB, Aug. 4, 2026 /CNW/ -- High Tide Inc. ("High Tide" or the "Company") (NASDAQ:HITI) (TSXV:HITI) (FSE: 2LYA), the high-impact, retail-forward enterprise built to deliver real-world value across every component of cannabis, is pleased to release guidance estimates regarding anticipated results for its third fiscal quarter ended July 31, 2026.Management Guidance Range (C$, MM)Implied SequentialChangeImplied Year Ov

Q2 2026 GAAP diluted EPS of $0.82 compared to $0.70 GAAP diluted EPS in Q2 2025 Q2 2026 non-GAAP diluted EPS of $1.27 compared to $1.10 non-GAAP diluted EPS in Q2 2025 Raises guidance for 2026 to the following: non-GAAP diluted EPS to $5.29 to $5.39, Adjusted EBITDA growth to mid to high-single digits, and sales growth to 4.5% to 5.5% Henry Schein, Inc. (NASDAQ:HSIC), the world’s largest provider of healthcare solutions to office-based dental and medical practitioners, today reported financial results for the second quarter ended June 27, 2026. "We delivered strong sales performance and margin improvement in the second quarter, driven by sustained momentum across our businesses

  Advanced Energy (NASDAQ:AEIS), a global leader in highly engineered, precision power conversion, measurement, and control solutions, today announced that it will participate at the following investor conferences. KeyBanc Technology Leadership Forum in Park City Date: Tuesday, August 11, 2026 Seaport Research Partners Annual Summer Investor Conference (Virtual) Date: Tuesday, August 18, 2026 Morgan Stanley 6th Nasdaq Virtual Investor Conference in Asia Date: Tuesday, August 18, 2026 Jefferies Semiconductor, IT Hardware & Communications Technology Conference in Chicago Date: Tuesday, August 25, 2026 Citi Global TMT Conference in New York City Date: Thursday, September 10, 2026 P

Reports second quarter 2026 EPS2 of $1.87 and adjusted EPS1,2 of $1.84 Raises full-year 2026 adjusted EPS guidance on strong commercial and operational execution, constructive biofuels environment, and momentum in Nutrition ADM (NYSE:ADM) today reported financial results for the quarter ended June 30, 2026 and updated its full-year 2026 outlook. 2Q26 Key Takeaways: Net earnings of $908 million, with adjusted net earnings1 of $895 million EPS2 of $1.87, with adjusted EPS1,2 of $1.84 2026 Outlook3: ADM now expects 2026 adjusted EPS1,2 of approximately $5.15 to $5.60, up from the prior adjusted EPS1,2 guidance range of $4.15 to $4.70 The updated outlook reflects expected y

Revenue of $730 million; pro forma revenue of $711 million; 4% pro forma revenue growth; 3% pro forma organic revenue growth GAAP EPS from continuing operations of $0.48; adjusted EPS from continuing operations of $1.41; GAAP pro forma EPS from continuing operations of $0.52; pro forma adjusted EPS from continuing operations of $1.41 Enters into definitive agreement to divest China Immunodiagnostics business Raises full year guidance Revvity, Inc. (NYSE:RVTY), today reported financial results for the second quarter ended July 5, 2026. The Company reported GAAP earnings per share from continuing operations of $0.48, as compared to $0.47 in the same period a year ago. Revenue f

– Second quarter net sales of $1.4 billion, up 22% year-over-year, organic sales(1) up 22% – GAAP net income of $136 million, down 31% year-over-year; Adjusted Earnings(1) of $250 million, up 53% year-over-year – Adjusted Operating EBITDA(1) of $431 million, up 24% year-over-year – GAAP EPS of $0.59, down 34% year-over-year; Adjusted EPS(1) of $1.19, up 53% year-over-year – Raises full year 2026 financial guidance Qnity Electronics, Inc. ("Qnity") (NYSE:Q) today reported results for the second quarter ended June 30, 2026. "We delivered our ninth consecutive quarter of profitable growth driven by disciplined execution across both segments," said Jon Kemp, Qnity’s Chief Executive Officer.

Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share and a growing global cannabis platform following its acquisition of Sanity Group GmbH ("Sanity"), announced today it will report earnings results for its third quarter ended June 30, 2026, on Tuesday, August 11, 2026, prior to market open. The Company will host a conference call to discuss its results with details as follows: Date: Tuesday, August 11, 2026 Time: 8:00 am Eastern Time To register for the conference call, please use this link: https://events.q4inc.com/analyst/401315111?pwd=q4Su5uEp To ensure you are connected for the full call, we suggest registe